Catalent Pharma Solutions completes second phase of expansion at Kansas City facility

Catalent Pharma Solutions has completed the second phase of its expansion programme, increasing the controlled-substance and controlled-temperature storage capabilities for its clinical supply business at its Kansas City facility.

The $5.5 million expansion will include a new Drug Enforcement Administration (DEA) Schedule I and II controlled substance vault (adding 3,600 sq. ft of storage) and additional controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations. Further to these, a new sampling room and an emergency generator have been added to ensure the security and integrity of samples in storage.

“Catalent customers have benefitted from our integrated analytical, oral solid manufacturing and clinical supply services which our Kansas City campus has offered continuously for over 18 years,” commented Kevin Economos, general manager of Clinical Supply Services at the site. “These latest expansions are critical enablers to our customers’ continued growth, that reinforce our comprehensive global network, and enhance Catalent’s role as a market leader in the clinical supply industry.”

The company’s Kansas City facility provides a range of fully integrated support services, from development and analytical support through to packaging and distribution. Expansions to this site, follow on from the company announcements of new capabilities and capacity at two of its other clinical supply facilities based in Philadelphia and Singapore.

Catalent is global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, with sites in the US, UK, Germany, Singapore, Japan and China, as well as an extended network of over 50 depots.